Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $24.15M (cash outflow) fell 53.7% year over year, behind the -26.3% change in trailing-twelve-month net income. Sequentially, it fell 82.8% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.
Context
- Net income amounted to 762355.6% of revenue in FY2025, up 200070.3 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$115.38M (-58.0%) for the fiscal year ending Dec 2026, a slowdown from the -20.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.15M-82.8% QoQ
- Last fiscal yearDec 2025
- -$274.45M-20.0% YoY
- LTMMar 2026
- -$246.41M-26.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -53.7% | +8.8% | +62.5 pp |
| 1 year | -20.0% | -58.0% | -38.0 pp |
| 3-year CAGR | +14.4% | -29.1% | -43.5 pp |
| 5-year CAGR | -29.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (274.45M) USD
- Year-over-year change
- +20.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (274.45M) | +20.0% |
| FY2024 | 2024-12-31 | (342.99M) | -46.2% |
| FY2023 | 2023-12-31 | (234.63M) | -28.1% |
| FY2022 | 2022-12-31 | (183.12M) | +26.8% |
| FY2021 | 2021-12-31 | (250.22M) | — |
Net Income vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.3% is the 7th highest of 10, against a peer median of +13.8%.
- Net income amounts to 794858.1% of revenue for LYEL, versus a peer median of 1968.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $246.41M USD | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $175.43M USD | +38.4% | +46.9% | — | |
| LTM Mar 2026 | $173.76M USD | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $166.01M USD | +74.3% | +67.3% | — | |
| LTM Mar 2026 | $156.4M USD | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $108.95M USD | -56.6% | -10.1% | 281.6% | |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
GNLXGenelux Corporation | LTM Mar 2026 | $33.58M USD | +13.8% | +83.4% | 419762.5% |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| LTM Mar 2026 | $5.23M USD | +106.0% | -28.4% | 2.4% | |
| Peer median (excluding LYEL) | — | +13.8% | +9.5% | 1968.6% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Depreciation & Amortization | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M |
| Deferred Income Tax | 39.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 62.2M | 0 | 47.08M | 33.14M | 41.83M |
| Change in Working Capital | 4.02M | (82.02M) | 3.42M | (3.12M) | (9.89M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 91K | 667K | 1.46M | (3.23M) | (2.34M) |
| Other Working Capital | 3.92M | (82.68M) | 1.96M | 114K | (7.56M) |
| Other Non-Cash Items | 4.62M | 79.11M | 183K | 130.95M | 80.95M |
| Operating Cash Flow | (126.25M) | (169.56M) | (163.69M) | (162.39M) | (150.02M) |
| Capital Expenditures | (65.5M) | (24.28M) | (2.69M) | (464K) | (780K) |
| Acquisitions (Net) | 673.47M | 0 | 0 | (31.35M) | (41.2M) |
| Purchases of Investments | (673.47M) | (406.32M) | (476.88M) | (394.71M) | (259.71M) |
| Sales of Investments | 617.4M | 419.05M | 663.61M | 548.94M | 374.68M |
| Other Investing Activities | (673.47M) | 0 | 0 | 0 | (18.9M) |
| Investing Cash Flow | (121.57M) | (11.54M) | 184.05M | 122.42M | 54.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.44M | (461K) | (457K) | (76K) | (1K) |
| Financing Cash Flow | 401.24M | 10.64M | 1.74M | 1.33M | 50.41M |
| Effect of Forex Changes | 0 | 186K | (4K) | 0 | 0 |
| Net Change in Cash | 153.42M | (170.27M) | 22.09M | (38.64M) | (45.52M) |
| Free Cash Flow | (191.75M) | (193.83M) | (166.38M) | (162.86M) | (150.8M) |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.